DAPK1 acts as a positive regulator of hypertension via induction of vasoconstriction
Clinical Science · 26.06.2025 · 139 (12) · 667-681
DOI: 10.1042/cs20255840 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, online erschienen am 18.06.2025. Verfasst von Xiuli Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Integrative Medicine, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Death-Associated Protein Kinases, Hypertension, Vasoconstriction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, China Association of Chinese Medicine.
Abstract (Originalsprache)
Death-associated protein kinase 1 (DAPK1) is a tumor suppressor gene involved in apoptosis, autophagy, and tumor progression. However, its role in hypertension (HTN) remains largely unexplored and lacks systematic evaluation. We administered adeno-associated virus (AAV) harboring short hairpin RNA targeting DAPK1 or control short hairpin RNA to male spontaneously hypertensive rats (SHRs) and Wistar-Kyoto rats. Additionally, wildtype and DAPK1 knockout mice were infused with angiotensin II (Ang II) or saline for four weeks. Male C57BL/6 mice underwent a four-week Ang II infusion and were treated with TC-DAPK6, a selective DAPK1 inhibitor. We examined the abdominal aortas (AAs) of mice and rats for pathological changes, measured blood pressure (BP) and pulse wave velocity using noninvasive BP methods, ultrasound, and hematoxylin and eosin staining. The role of DAPK1 in early HTN was further assessed through immunofluorescence, ex vivo isometric constriction of the AA, RNA sequencing, Western blot, and immunohistochemistry. Our study demonstrated that the targeted inhibition of DAPK1 with AAV significantly ameliorated HTN in SHRs and reduced damage to the AAs and target organs, including the heart and kidneys. Meanwhile, DAPK1 knockout or inhibition in mice significantly ameliorates Ang II-induced HTN in mice, as well as reducing damage to the AAs and target organs, including the heart and kidneys. Mechanistically, DAPK1 inhibition prevents myosin light chain (MLC) phosphorylation at serine 19, reducing vasoconstriction and protecting against HTN. In conclusion, DAPK1 is involved in HTN pathogenesis by regulating the MLC pathway to mediate vascular constriction, highlighting potential as a therapeutic target for HTN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Integrative Medicine, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
- Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Med-icine, Fuzhou, Fujian, China.
- Fujian Collaborative Innovation Center for Integrative Medicine in Prevention and Treatment of Major Chronic Cardiovascular Diseases, Fuzhou, Fujian, China.
- Department of Cardiology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
- National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing, China.
- Central Laboratory at the Second Affiliated Hospital of Fujian Traditional Chinese Medical University, Fuzhou, Fujian, China.
ORCID-Profile: Xiuli Zhang, Yao Lin, Jun Peng, Aling Shen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- China Association of Chinese Medicine
- Development Fund of Chen Keji Integrative Medicine
- youth talent support program from Fujian University of Traditional Chinese Medicine
Zitieren
APA
Zhang, X., Cheng, Y., Lu, Y., Xu, N., Guo, Z., Wu, M., Lin, G., Yao, M., Yang, Y., Lin, Y., Peng, J., & Shen, A. (2025). DAPK1 acts as a positive regulator of hypertension via induction of vasoconstriction. Clinical Science, 139(12), 667-681. https://doi.org/10.1042/cs20255840
Vancouver
Zhang X, Cheng Y, Lu Y, Xu N, Guo Z, Wu M, et al. DAPK1 acts as a positive regulator of hypertension via induction of vasoconstriction. Clinical Science. 2025;139(12):667-681. doi:10.1042/cs20255840
BibTeX
@article{Zhang2025,
author = {Zhang, Xiuli and Cheng, Ying and Lu, Yao and Xu, Nanhui and Guo, Zhi and Wu, Meizhu and Lin, Guosheng and Yao, Mengying and Yang, Yanyan and Lin, Yao and Peng, Jun and Shen, Aling},
title = {DAPK1 acts as a positive regulator of hypertension via induction of vasoconstriction},
journal = {Clinical Science},
year = {2025},
volume = {139},
number = {12},
pages = {667--681},
doi = {10.1042/cs20255840}
}
EUVIMED